Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2

Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2

Monoclonal antibodies (mAbs) targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein have demonstrated clinical efficacy in preventing or treating coronavirus disease 2019 (COVID-19), resulting in the emergency use authorization (EUA) for several SARS-CoV-2 targeting...

Full description

Bibliographic Details
Main Authors: Yun Ji, Qi Zhang, Lin Cheng, Jiwan Ge, Ruoke Wang, Mengqi Fang, Eric M. Mucker, Peng Chen, Ji Ma, Rui Zhang, Chunming Li, Holly Hammond, Lauren Baracco, Michael Holbrook, Matthew Frieman, Zheng Zhang, Xinquan Wang, Jay W. Hooper, Linqi Zhang, Qing Zhu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Immunology
Subjects:
monoclonal antibody (mAb)
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
receptor binding domain (RBD)
M252Y/S254T/T256E (YTE)
amubarvimab (BRII-196)
romlusevimab (BRII-198)
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.980435/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.980435/full

Similar Items